Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | CASP3 | P42574 | 1/20 | 0.81 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.81 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.81 |
| ▸ | RAB9A | P51151 | 6/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.76 |
| ▸ | NPC1 | O15118 | 4/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10943445 | 0.92 | RAB9A (0.88) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL5879030 | 0.92 | RAB9A (0.88) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL4122958 | 0.89 | MAPT (1.00) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL4724997 | 0.86 | SMN1; SMN2 (1.00) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4570567 | 0.85 | KMT2A (0.75) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL62862 | 0.85 | KMT2A (0.75) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL9449917 | 0.85 | RAB9A (0.76) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL6707294 | 0.85 | RAB9A (0.76) | MAPTMEN1KMT2ACASP3TRPV1 | |
| SCHEMBL10939388 | 0.84 | SMN1; SMN2 (0.91) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3637607 | 0.84 | RAB9A (1.00) | MAPTMEN1KMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905306-B2 | Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus | SOUTHERN RESEARCH INSTITUTE (US) | 2024-02-20 | — | — | US | disclosed |
| WO-2023122212-A2 | SUBSTITUTED PHENYL ETHYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-29 | — | — | WO | disclosed |
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE | 2023-06-22 | — | — | US | disclosed |
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | COPPOLA GARY M | 2006-09-14 | — | — | US | disclosed |
| EP-1590319-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Novartis AG (CH) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004065351-A1 | AMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | NOVARTIS AG (CH) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | MAPT 4767/4885MEN1 1373/4885KMT2A 1521/4885 |
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SARS1, ACE2, ACE | MAPT 1318/4885MEN1 3847/4885KMT2A 1036/4885 |
| US-11905306-B2 | Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of SARS virus | SARS1, ACE2, TMPRSS2 | MAPT 1196/4885MEN1 3926/4885KMT2A 882/4885 |
| US-20060205772-A1 | Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type I | HSD11B1, HSD11B2, CYP11B1 | MAPT 4655/4885MEN1 2546/4885KMT2A 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.